OneChain Immunotherapeutics secures €6.7M in pre-series A funding round led by Invivo Capital

by Invivo Capital

The transaction was led by the venture capital firm Invivo Capital, with the participation of the current investors, the Josep Carreras Leukemia Foundation and the Centre for Technological Development...

Read more

Integra Tx secures €4.5-million in funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures

by Invivo Capital

Integra Therapeutics (Integra Tx), a biotechnology company that is creating next-generation gene editing tools to boost the efficiency and safety of advanced therapies, has completed its first round o...

Read more

Arthex secures €4.25M from Invivo Ventures and Advent France Biotechnology

by Invivo Capital

Arthex Biotech (ARTHEx), a preclinical stage life sciences company focused on the development of the next generation antisense RNA therapies for the treatment of Myotonic Dystrophy Type 1 (DM1), today...

Read more

A new cancer immune therapy spin-off of Hospital Clínic-IDIBAPS (Barcelona) secures a 1.5 million-euro investment from Invivo Ventures

by Invivo Capital

Hospital Clínic – IDIBAPS (Barcelona) has founded Gyala Therapeutics, a new spin-off company focused on developing new CAR-T therapies for treating hematological malignancies. The company raised

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Mediterrania Capital Partners completes ...

by Mediterrania Capital Partners

Over the tenure of MC III’s investment, TGCC has not only achieved f...

Photos Stream